Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study

Fig. 3

Differential in time to flare according to the definitions of flare used. Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI) and British Isles Lupus Assessment Group disease activity index (BILAG) scores were collected only at prespecified time points (months 0, 3 and 6 and then every 6 months; however, the graphed points are exact dates when the per-protocol visits actually occurred), and reflected only the systemic lupus erythematosus activity within a maximum 30-day time window before each visit. Changes in glucocorticoids and/or immunosuppressive therapy were tracked using the source documentation, and thus these data have finer granularity in time (analysis with the Kaplan-Meier approach for survival estimation). GC glucocorticoids, IS immunosuppressants

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us